CSL
Outcomes have fallen short of expectations: CSL
CSL share price tumbles to 10-year low on back of US$5 billion asset write-off Australian pharmaceutical and biotechnology firm, CSL, is cutting its full-year revenue and earnings forecasts following a 90-day review by interim chief …
Flu cases at record levels
Patients urged to get flu shot as confirmed cases surpass 42,000 in three months Influenza case numbers for the first quarter of 2025 are tracking close to 50% higher than …
The ‘Ozempic effect’ hits worldwide share market
Whether health industry or junk food business, steamroller popularity of weight loss drug shakes up stock prices The huge success of the new wave of GLP-1 (glucagon-like peptide-1) receptor agonist …
Vaccines shine for CSL
In “difficult global environment” vaccines division managed 16% profit increase CSL’s newly-renamed vaccines division CSL Seqirus has been one of the brightest divisions for the Australian pharmaceutical giant, with both …
Vaccine maker’s Covid scare
CSL’s Melbourne Broadmeadows facility had a positive COVID-19 case One of the CSL production facilities producing the Astra Zeneca Covid vaccine, Vaxzevria, has had a positive COVID-19 case of its own, …
Vaccine questions confronted
Minister and health officials talk up Australia’s vaccine program as first clotting case emerges and questions over speed continue Health Minister Greg Hunt and leading medical officials have moved to …
Leading the pack
Who are the world’s leading pharmaceutical companies? These are the top 20 New statistics collated by UK data and analytics agency GlobalData has revealed the world’s 20 leading pharmaceutical companies …
CSL profits up
Double digit sales growth in albumin and speciality products and influenza vaccine sales have helped CSL announce a net profit after tax of US$692m (A$889m) for the six months ended …